iRhythm Technologies, Inc. Shares Preliminary Fourth Quarter 2025 Highlights and Business Update at the 44th Annual J.P. Morgan Healthcare Conference

Core Insights - iRhythm Technologies, Inc. has reported a transformative year in 2025, achieving over 25% year-over-year revenue growth and free cash flow positivity for the first time in its history [3] Operational Highlights - The company has recorded strong commercial volumes and is well-positioned for growth in 2026 with multiple catalysts, including deeper penetration in primary care and population health through AI partnerships [3] - iRhythm's clinical evidence program, including AVALON and CAMELOT publications, supports the clinical superiority of its Zio LTCM product, which is expected to expand into additional populations and care settings [3] Financial Outlook - For full year 2025, revenue is anticipated to exceed the high end of the previously stated guidance range of $740 million, driven by record revenue unit volume in Q4 2025 [7] - The company expects revenue for 2026 to be approximately $870 million to $880 million, representing a year-over-year growth of about 17% to 18%, with an adjusted EBITDA margin of approximately 11.5% to 12.5% [7] Clinical Evidence - Recent real-world evidence from over 1.4 million patients reinforces the clinical superiority of Zio LTCM, with data demonstrating consistent performance in Asian populations and validating successful at-home self-application for earlier detection in at-risk populations [7]